BLC
ALNY icon

Brown, Lisle/Cummings’s Alnylam Pharmaceuticals ALNY Stock Holding History

Brown, Lisle/Cummings’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.4K Buy
164
+2
+1% +$603 0.01% 396
2026
Q1 		$53.6K Buy
162
+30
+23% +$10.2K 0.01% 350
2025
Q4 		$52.5K Hold
132
– – 0.01% 338
2025
Q3 		$60.2K Hold
132
– – 0.02% 323
2025
Q2 		$43K Hold
132
– – 0.01% 350
2025
Q1 		$35.6K Buy
132
+7
+6% +$1.8K 0.01% 361
2024
Q4 		$29.4K Hold
125
– – 0.01% 375
2024
Q3 		$34.4K Hold
125
– – 0.01% 346
2024
Q2 		$30.4K Hold
125
– – 0.01% 350
2024
Q1 		$18.7K Hold
125
– – 0.01% 378
2023
Q4 		$23.9K Hold
125
– – 0.01% 346
2023
Q3 		$22.1K Hold
125
– – 0.01% 329
2023
Q2 		$23.7K Hold
125
– – 0.01% 325
2023
Q1 		$25K Hold
125
– – 0.01% 317
2022
Q4 		$29.7K Buy
+125
New +$26.7K 0.02% 298

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brown, Lisle/Cummings's ALNY Position: Q2 2026 in Review

Brown, Lisle/Cummings increased its Alnylam Pharmaceuticals (ALNY) stake by 1.2% in Q2 2026, buying an estimated $603 and bringing the position to 164 shares worth $49.4K. The position accounts for 0.01% of the portfolio, ranked #396.

Brown, Lisle/Cummings first reported a position in ALNY in Q4 2022 and has held it in 15 quarters since. The position peaked at $60.2K in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Brown, Lisle/Cummings held 164 shares of Alnylam Pharmaceuticals worth $49.4K as of Q2 2026.
  • Brown, Lisle/Cummings bought 2 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $603.
  • Alnylam Pharmaceuticals made up 0.01% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #396 holding.
  • Brown, Lisle/Cummings first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Brown, Lisle/Cummings's Alnylam Pharmaceuticals position peaked at $60.2K in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.